NLRP3 and glaucoma: However, in the more clinically relevant microbead-induced mouse model of glaucoma, where IOP was elevated, treatment with a commercially available NLRP3-specific inhibitor (MCC950) [118] was also shown to prevent axon degeneration and death of RGCs [119].